Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, B-Cell 6Lymphoma 4Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Leukemia 2Burkitt Lymphoma 2Recurrence 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Follicular 1Hematologic Neoplasms 1

Interventions

Cytarabine 21Imatinib Mesylate 20venetoclax 16Azacitidine 16nilotinib 15Cyclophosphamide 15fludarabine 13Dasatinib 12blinatumomab 10Rituximab 10quizartinib 7Gemtuzumab 7Daunorubicin 7ruxolitinib 6Drug Therapy 6Clofarabine 6Bendamustine Hydrochloride 6AP 1903 reagent 6ponatinib 5fludarabine phosphate 5Whole-Body Irradiation 5Vincristine 5Mycophenolic Acid 5Methotrexate 5Granulocyte Colony-Stimulating Factor 5Dexamethasone 5vosaroxin 4revumenib 4rasburicase 4forodesine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia × Inotuzumab Ozogamicin × Clear all
NCT05748171 2026-05-14

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

Pfizer

Phase 2 Recruiting
100 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03677596 2023-11-22

A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients

Pfizer

Phase 4 Completed
102 enrolled 27 charts
LymphoidOther hematologic neoplasm

Leukemia, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡